YL0712-3, a Novel ATR/ATM Inhibitor, Demonstrates Anti-Tumor Activity in TP53 Mutant DLBCL through Synthetic Lethality and Degradation of Mutant p53
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-207718
Abstract: Background: Patients with diffuse large B-cell lymphoma (DLBCL) harboring TP53 mutations (TP53mut DLBCL) face a dismal prognosis and currently lack a standardized treatment regimen. Both ATR (Ataxia Telangiectasia and Rad3-related protein) and ATM (Ataxia Telangiectasia… read more here.
Keywords: dlbcl; tp53 mutant; mutant; yl0712 ... See more keywords